Monocarboxylate transporter 1 (MCT1) facilitates the transport of important metabolic fuels (lactate, pyruvate and ketone bodies) and possibly also acidic drugs such as valproic acid across the blood-brain barrier. Because an impaired brain energy metabolism and resistance to antiepileptic drugs are common features of temporal lobe epilepsy (TLE), we sought to study the expression of MCT1 in the brain of patients with this disease. Immunohistochemistry and immunogold electron microscopy were used to assess the distribution of MCT1 in brain specimens from patients with TLE and concomitant hippocampal sclerosis (referred to as mesial TLE or MTLE (n = 15)), patients with TLE and no hippocampal sclerosis (non-MTLE, n = 13) and neurologically normal autopsy subjects (n = 8). MCT1 was present on an extensive network of microvessels throughout the hippocampal formation in autopsy controls and to a lesser degree in non-MTLE. Patients with MTLE were markedly deficient in MCT1 on microvessels in several areas of the hippocampal formation, especially CA1, which exhibited a 37% to 48% loss of MCT1 on the plasma membrane of endothelial cells when compared with non-MTLE. These findings suggest that the uptake of blood-derived monocarboxylate fuels and possibly also acidic drugs, such as valproic acid, is perturbed in the epileptogenic hippocampus, particularly in MTLE. We hypothesize that the loss of MCT1 on brain microvessels is mechanistically involved in the pathophysiology of drug-resistant TLE, and propose that re-expression of MCT1 may represent a novel therapeutic approach for this disease.
Introduction
Despite recent advances in the treatment of epilepsy in humans, as many as 40% of patients suffering from temporal lobe epilepsy (TLE) cannot control their seizures with current antiepileptic drugs. The development of more efficacious therapies against TLE is requisite, and a better understanding of the underlying mechanisms of drugresistant TLE is likely to facilitate the discovery of novel therapeutic targets for this disease.
TLE is characterized by recurrent episodes of partial seizures that may or may not be secondarily generalized. The seizures in TLE involve a network of temporal lobe and limbic structures such as the hippocampal formation, entorhinal cortex, amygdala, lateral temporal neocortex, medial thalamus and inferior frontal lobes (Spencer, 2002) .
Approximately 70% of patients treated for drug-resistant TLE with surgical resection of the anteromedial temporal lobe, exhibit hippocampal sclerosis, which is characterized by astroglial proliferation and preferential loss of neurons particularly in CA1, CA3 and the dentate hilus of the hippocampal formation (de Lanerolle et al., 2003; Gloor, 1991; Sommer, 1880) . Depth electrode recordings indicate that the sclerotic hippocampus is the focus of the seizures in patients with this pathology (Spencer, 1994) , and surgical resection of the sclerotic hippocampus is associated with excellent seizure control in about 85% of patients (de Lanerolle et al., 2003) . Patients with TLE and concomitant hippocampal sclerosis are here classified as mesial temporal lobe epilepsy (MTLE) .
Approximately 30% of patients surgically treated for TLE do not exhibit hippocampal sclerosis (de Lanerolle et al., 2003) . These "non-
